Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics announced an amendment modifying both the contract period end date and the non-disclosure deadline for a contract manufacturing LOI signed with a European pharmaceutical company to October 31, 2024.
📊 [Key Disclosure Details & Summary Statistics]
- Disclosure Type: Correction Report (Original Disclosure Date: 2022-04-25)
- Reason for Correction: Modification of non-disclosure date as requested by the client
- Corrected Items (Contract Period & Non-Disclosure Postponement Date):
- Contract Period: (Before) 2022-04-25 – 2024-08-31 → (After) 2022-04-25 – 2024-10-31
- Postponement Deadline for Counterparty Disclosure: (Before) 2024-08-31 → (After) 2024-10-31
- Summary of Original Disclosure (Execution of Contract Manufacturing LOI):
- Counterparty: Pharmaceutical company located in Europe (Undisclosed due to trade secrecy)
- Contract Amount: KRW 154,093,728,300 (KRW ~154.1B) / USD 124,099,000
- Contract Ratio to Recent Annual Revenue: 9.38% (Based on 2021 annual revenue of KRW 1,568,006,928,039)
- LOI Execution Date: April 25, 2022
- Board Resolution Date or Fact Confirmation Date: April 25, 2022
- Other Key Investment Matters:
- The contract amount was converted using the initial FX rate of USD/KRW 1,241.70 on April 25, 2022, based on the confirmed amount of USD 124,099,000.
- The agreement is legally binding between both parties, and definitive details will be disclosed upon execution of the formal main contract.
- The scheduled counterparty disclosure date is subject to change in the future.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Tracking Execution of Main Contract and Non-Disclosure Extensions
This amendment reflects a modification of the contract end date and the counterparty non-disclosure deadline to October 31, 2024. Checking whether a definitive main contract disclosure is filed within the revised deadline—or if further amendments are submitted to extend the period again—is important for understanding the progress and finalization status of the transaction. Relevant updates can be verified through subsequent disclosures or periodic reports.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided strictly for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
